PHARMACOLOGY

John CLARKE

SITE

Toxins (Basel). 2021;13:537. Microcystin toxicokinetics, molecular toxicology, and pathophysiology in preclinical rodent models and humans. Arman T, Clarke JD. PubMed

Pharmacol Rev. 2021;73:847-859. Modeling pharmacokinetic natural product-drug interactions for decision-making: A NaPDI Center Recommended Approach. Cox EJ, Tian DD, Clarke JD, Rettie AE, Unadkat JD, Thummel KE, McCune JS, Paine MF. PubMed

Phytother Res. 2021;35:3286-3297. Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.  Lynch KD, Montonye ML, Tian DD, Arman T, Oyanna VO, Bechtold BJ, Graf TN, Oberlies NH, Paine MF, Clarke JD. PubMed

Biochem Pharmacol. 2020;174:113780. Interaction of Oatp1b2 expression and nonalcoholic steatohepatitis on pravastatin plasma clearance. Toth EL, Clarke JD, Csanaky IL, Cherrington NJ. PubMed

J Pharmacol Exp Ther. 2019;371:385-393. A pharmacokinetic natural product-disease-drug interaction: A double hit of Silymarin and nonalcoholic steatohepatitis on hepatic transporters in a rat model. Montonye ML, Tian DD, Arman T, Lynch KD, Hagenbuch B, Paine MF, Clarke JD. PubMed

Toxicon. 2019;162:1-8. Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity. Clarke JD, Dzierlenga A, Arman T, Toth E, Li H, Lynch KD, Tian DD, Goedken M, Paine MF, Cherrington N. PubMed

Drug Metab Dispos. 2018;46:1478-1486. Gene-by-environment interaction of Bcrp-/- and Methionine- and Choline-deficient diet-induced onalcoholic steatohepatitis alters SN-38 disposition. Toth EL, Li H, Dzierlenga AL, Clarke JD, Vildhede A, Goedken M, Cherrington NJ. PubMed

Liver Int. 2017;37:1074-1081. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. Clarke JD, Novak P, Lake AD, Hardwick RN, Cherrington NJ. PubMed

Drug Metab Dispos. 2016;44:1799-1807. Nonalcoholic steatohepatitis modulates membrane protein retrieval and insertion processes. Dzierlenga AL, Clarke JD, Cherrington NJ. PubMed

Biochem Pharmacol. 2016;115:144-51. Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovirLaho T, Clarke JD, Dzierlenga AL, Li H, Klein DM, Goedken M, Micuda S, Cherrington NJ. PubMed

J Pharmacol Exp Ther. 2016;358:246-53. Biliary elimination of Pemetrexed is dependent on Mrp2 in rats: Potential mechanism of variable response in Nonalcoholic Steatohepatitis. Dzierlenga AL, Clarke JD, Klein DM, Anumol T, Snyder SA, Li H, Cherrington NJ. PubMed

Diabetes. 2015;64:3305-13 Mechanism of altered Metformin distribution in Nonalcoholic Steatohepatitis. Clarke JD, Dzierlenga AL, Nelson NR, Li H, Werts S, Goedken MJ, Cherrington NJ. PubMed

Pharmacol Ther. 2015;151:99-106. Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Clarke JD, Cherrington NJ. PubMed

J Pharmacol Exp Ther. 2015;352:462-70. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. Dzierlenga AL, Clarke JD, Hargraves TL, Ainslie GR, Vanderah TW, Paine MF, Cherrington NJ. PubMed

Drug Metab Dispos. 2015;43:266-72. Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis. Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Goedken MJ, Cherrington NJ. PubMed

Toxicol Sci. 2014;142:45-55. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Hardwick RN, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ. PubMed

J Hepatol. 2014;61:139-47. Synergistic interaction between genetics and disease on pravastatin disposition. Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ. PubMed

J Pharmacol Exp Ther. 2014;348:452-8. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression. Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ. PubMed

Drug Metab Dispos. 2014;42:586-95. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ. PubMed

Drug Metab Dispos. 2014;42:596-602. Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in mice. Merrell MD, Nyagode BA, Clarke JD, Cherrington NJ, Morgan ET. PubMed

Drug Metab Dispos. 2013;41:353-61. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW.  PubMed

Expert Opin Drug Metab Toxicol. 2012;8:349-60. Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Clarke JD, Cherrington NJ. PubMed